QNCX Quince Therapeutics Inc

Price (delayed)

$2.05

Market cap

$74.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.74

Enterprise value

$27.22M

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence ...

Highlights
The quick ratio has soared by 127% YoY and by 69% from the previous quarter
The debt has shrunk by 83% YoY
The equity has decreased by 22% YoY but it has increased by 4.8% QoQ

Key stats

What are the main financial stats of QNCX
Market
Shares outstanding
36.1M
Market cap
$74.01M
Enterprise value
$27.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$83.59M
EBITDA
-$83.3M
Free cash flow
-$63.28M
Per share
EPS
-$2.74
Free cash flow per share
-$1.95
Book value per share
$3.7
Revenue per share
$0
TBVPS
$3.42
Balance sheet
Total assets
$117.86M
Total liabilities
$6.33M
Debt
$133,000
Equity
$111.53M
Working capital
$93.42M
Liquidity
Debt to equity
0
Current ratio
16.7
Quick ratio
15.91
Net debt/EBITDA
0.56
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-64.8%
Return on equity
-71%
Return on invested capital
-152.9%
Return on capital employed
-74.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QNCX stock price

How has the Quince Therapeutics stock price performed over time
Intraday
-7.66%
1 week
-11.26%
1 month
-5.53%
1 year
-97.73%
YTD
-83.76%
QTD
-7.66%

Financial performance

How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.59M
Net income
-$83.31M
Gross margin
N/A
Net margin
N/A
QNCX's operating income is up by 6% since the previous quarter and by 4.9% year-on-year
The net income rose by 6% QoQ and by 4.1% YoY

Growth

What is Quince Therapeutics's growth rate over time

Valuation

What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
0.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 8% since the previous quarter and by 7% year-on-year
QNCX's P/B is 92% below its last 4 quarters average of 6.5
The equity has decreased by 22% YoY but it has increased by 4.8% QoQ

Efficiency

How efficient is Quince Therapeutics business performance
The ROIC has dropped by 63% year-on-year
Quince Therapeutics's ROA has decreased by 36% YoY and by 2.2% from the previous quarter
The ROE has decreased by 34% YoY

Dividends

What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QNCX.

Financial health

How did Quince Therapeutics financials performed over time
The current ratio has soared by 128% YoY and by 68% from the previous quarter
The quick ratio has soared by 127% YoY and by 69% from the previous quarter
The debt is 100% lower than the equity
QNCX's debt to equity has dropped by 100% year-on-year
The debt has shrunk by 83% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.